MO8833A_supplementary_materials_v2_tables.pdf (239.75 kB)
Supplementary Tables – Indirect comparison of pembrolizumab monotherapy versus nivolumab+ipilimumab in first-line metastatic lung cancer
dataset
posted on 2022-01-25, 09:05 authored by Figshare Future Science GroupFigshare Future Science Group, Balazs Halmos, Thomas Burke, Chrysostomos Kalyvas, Ralph Insinga, Kristel Vandormael, Andrew Frederickson, Bilal Piperdi|
Table S1 Base case scenario of overall survival and progression-free survival in patients with PD-L1 TPS≥1% before matching
Table S2 Landmark analysis of overall survival and progression-free survival for chemotherapy arms from KN024/KN042 and CheckMate 227 Part 1a in patients with PD-L1 TPS≥1% before and after matching
Table S3 Pembrolizumab versus nivolumab+ipilimumab for overall survival and progression-free survival in patients with PD-L1 TPS≥1%, TPS≥50% and TPS 1–49% |
